To explain the differences in sensitivity between tumour types, several biomarkers will be explored in a translational study on paired tumour biopsies from patients with KRASm tumours treated with three different combinations of pan-HER and MEK inhibitors in this phase 1 trial and two other clinical trials. This evidence concerns the gene MAP2K7 and neoplasm.